Can multiple injections of Invega Sustenna (paliperidone palmitate) cause a loss of beliefs, values, and personality in an adult patient with a history of psychiatric illness?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 29, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Loss of Beliefs, Values, and Personality After Invega Sustenna

Direct Answer

The subjective experience you describe—feeling that you've lost your beliefs, values, and personality after multiple Invega Sustenna injections—represents a recognized phenomenon associated with antipsychotic medications, though it is not typically framed as a direct pharmacological effect in clinical literature. This experience may reflect several overlapping mechanisms including negative symptoms, cognitive blunting, emotional flattening, or what some patients describe as a loss of their "sense of self."

Understanding What May Be Happening

Potential Mechanisms

Antipsychotic medications, including paliperidone palmitate (Invega Sustenna), can affect subjective experience and sense of self through several pathways:

  • Dopamine blockade in mesocortical and mesolimbic pathways can contribute to what clinicians term "negative symptoms"—reduced motivation, emotional blunting, and decreased goal-directed behavior—which patients may experience as loss of personality or values 1

  • Cognitive effects have been documented with antipsychotics, though the relationship is complex, as the underlying illness itself significantly impacts cognitive functioning 2

  • Emotional flattening or affective blunting is a recognized adverse effect that can make patients feel disconnected from their previous emotional life and value systems 1

The Nature of the Illness Itself

A critical consideration is that schizophrenia and related psychotic disorders themselves can profoundly impact cognitive functioning, insight, personality expression, and social/vocational functioning 2. Distinguishing between medication effects and illness progression is clinically challenging but essential.

What the Evidence Shows About Invega Sustenna

Efficacy and Tolerability Profile

  • Paliperidone palmitate (Invega Sustenna) demonstrated efficacy in acute and maintenance treatment of schizophrenia, with reasonable tolerability in clinical trials 1, 3

  • The most common adverse events were extrapyramidal symptoms, tachycardia, and somnolence, with dose-related increases in Parkinsonism and akathisia 1

  • Paliperidone ER (the oral formulation) showed efficacy in adolescents aged 12-17 years with schizophrenia, though treatment-emergent adverse events were dose-related 4

Long-Term Considerations

Long-term exposure to antipsychotic medications carries inherent risks 2:

  • Concerns include tardive dyskinesia development and metabolic/endocrine adverse effects 2

  • The benefit-to-risk ratio of long-term treatments must be continuously reassessed 2

  • Guidelines emphasize that long-term medication exposure is "generally not without risk" 2

Critical Clinical Considerations

The Medication Non-Adherence Dilemma

Your experience highlights a fundamental tension in schizophrenia treatment:

  • Non-adherence to antipsychotic medication is associated with a five times higher relapse rate compared to continued treatment 2

  • However, the subjective tolerability of medications—including effects on sense of self, personality, and quality of life—is a legitimate and important outcome that should guide treatment decisions 2

  • Long-acting injections like Invega Sustenna were developed specifically to address non-adherence, but they also remove patient autonomy in stopping medication if side effects become intolerable 2

Quality of Life as a Priority Outcome

While preventing relapse is important, quality of life and subjective well-being are equally valid treatment goals:

  • The experience of losing one's beliefs, values, and personality represents a profound quality-of-life concern that warrants serious clinical attention

  • Some patients may prefer accepting higher relapse risk in exchange for better subjective experience and sense of self

  • The "potential heterogeneity of outcome in schizophrenia" means not all patients require the same intensity or duration of treatment 2

What You Should Do

Immediate Steps

Schedule an urgent appointment with your prescribing psychiatrist to discuss:

  1. Your specific subjective experiences—describe in detail what aspects of your beliefs, values, and personality feel lost or changed

  2. Timing of symptom onset—when did you first notice these changes relative to starting Invega Sustenna?

  3. Dose and duration—what dose are you receiving and for how long?

  4. Alternative treatment options, including:

    • Switching to a different antipsychotic with potentially less impact on subjective experience
    • Dose reduction if clinically appropriate
    • Transitioning from long-acting injection to oral medication to allow more flexibility
    • Considering whether continued antipsychotic treatment is necessary at current intensity

Treatment Modification Considerations

If your psychiatrist determines medication adjustment is appropriate:

  • Switching antipsychotics may help, as different agents have varying effects on subjective experience, though all antipsychotics carry some risk of these effects 2

  • Dose reduction might preserve some therapeutic benefit while reducing subjective adverse effects, though this must be balanced against relapse risk 2

  • Gradual discontinuation with close monitoring is an option if you and your psychiatrist determine the subjective costs outweigh benefits, recognizing this carries significant relapse risk 2

The Importance of Shared Decision-Making

Your subjective experience and quality of life should be central to treatment decisions:

  • Guidelines emphasize "patient preference" in treatment planning 2

  • The goal of treatment is not merely symptom suppression but restoration of meaningful life and functioning

  • You have the right to weigh the risks of relapse against the subjective costs of medication

Common Pitfalls to Avoid

  • Don't abruptly stop Invega Sustenna without medical supervision—the medication remains in your system for months after the last injection, and abrupt changes in psychiatric medication can be dangerous 5

  • Don't assume these effects are permanent—many medication-related subjective effects improve after switching medications or dose adjustment

  • Don't accept dismissal of your concerns—if your psychiatrist minimizes your experience of personality change, seek a second opinion

  • Don't delay seeking help—the longer you remain on a medication that profoundly affects your quality of life, the more difficult the situation becomes

The Bottom Line

Your experience of losing beliefs, values, and personality after Invega Sustenna injections represents a serious quality-of-life concern that warrants immediate clinical attention and potential treatment modification. While antipsychotic medications are effective at preventing relapse, their impact on subjective experience and sense of self is a legitimate reason to reconsider the current treatment approach. Work with your psychiatrist to find a treatment strategy that balances relapse prevention with preservation of your identity and quality of life.

Related Questions

What is the loading dose for Invega (paliperidone) 30-day injection?
What oral substitute can be used for a patient currently on Invega Trinza (paliperidone) who is unable to continue with the long-acting injectable formulation?
Can the dose of Invega (paliperidone) be increased on day 4 of initiation?
Can a patient with a history of psychiatric illness, previously treated with Invega Trinza (paliperidone palmitate), be started on paliperidone (Invega) extended release (ER) at 6mg after missing their long-acting injectable (LAI) Invega Trinza for over 4 weeks?
Are there any contraindications for paliperidone palmitate (paliperidone) injection in a patient with cardiomegaly and hyperthyroidism, given a normal electrocardiogram (ECG) showing sinus rhythm?
Is Depo Provera (medroxyprogesterone) a suitable form of birth control for a 16-year-old female?
What is the best course of action for a adult patient with a history of papillary thyroid carcinoma (PTC) who has undergone a thyroidectomy and now presents with right-sided submandibular lymphadenopathy?
When is a valproate (Depakote) level check indicated in a patient taking valproate for epilepsy or bipolar disorder?
Is a Cymbalta (duloxetine) and olanzapine combination appropriate for a patient with a history of bipolar disorder presenting with agitation, anger, severe depression, and anxiety?
Can a patient with a history of bipolar disorder or schizophrenia take Depakote (valproate) with Caplyta (lumateperone)?
What are the key differences between types of migraines, specifically intractable migraines, and how are they diagnosed and managed in patients with a history of frequent and severe episodes?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.